Brain network may be vulnerable to Alzheimer’s and schizophrenia

1 December 2014

Oxford University researchers have found a network of brain regions that appears to be more vulnerable to unhealthy ageing – such as Alzheimer's disease – and also seems susceptible to disorders that emerge in young people, such as schizophrenia.

The team showed that, in healthy people, these parts of the brain are the last to develop and the first to show signs of neurodegeneration.

The research, the largest study of its kind, is published in the journal Proceedings of the National Academy of Sciences. It was led by Medical Research Council (MRC)-funded researcher Dr Gwenaëlle Douaud, at Oxford University’s Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB).

New data show vaccines reduce severe COVID-19 in older adults

2 March 2021

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

25 February 2021

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

24 February 2021

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Three ways virtual reality could transform mental health treatment

22 February 2021

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

22 February 2021

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Reprogramming tumour cells using an antimalarial drug

18 February 2021

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.